Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on May 24, 2016. The filing covers events occurring on May 24, 2016, including the approval of a short-term incentive plan for executive officers and the results of the annual meeting of stockholders.

Key Financial Metrics

The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.

Material Changes and Executive Compensation

On May 24, 2016, the Compensation Committee approved a 2016 Short Term Incentive Plan for executive officers. Cash bonuses are based on a percentage of base salary and achievement of corporate goals:

  • Thomas Looby (CEO): Target bonus of 50% of annual base salary.
  • Max Scheder-Bieschin (CFO): Target bonus of 40% of annual base salary.
  • Russ Angold (President, Ekso Labs): Target bonus of 30% of annual base salary.

Performance criteria are weighted as follows:

  • Looby and Scheder-Bieschin: 85% Strategic and Medical Goals; 15% Industrial Goals.
  • Angold: 50% Strategic and Medical Goals; 50% Industrial Goals.

The Compensation Committee retains discretion to adjust awards based on company cash resources as of December 31, 2016.

Stockholder Vote Results

At the Annual Meeting held on May 24, 2016, stockholders voted on two proposals:

Proposal 1: Election of Directors

Director Nominee For Withheld Broker Non-Votes
Steven Sherman 26,898,713 5,158,823 34,057,300
Thomas Looby 31,693,008 364,528 34,057,300
Daniel Boren 30,476,988 1,580,548 34,057,300
Marilyn Hamilton 30,509,140 1,548,396 34,057,300
Jack Peurach 30,402,758 1,654,778 34,057,300
Stanley Stern 30,483,726 1,573,810 34,057,300
Amy Wendell 30,452,670 1,604,866 34,057,300

Proposal 2: Ratification of Auditors

OUM & Co., LLP was ratified as the independent registered public accounting firm.

  • For: 64,588,514
  • Against: 847,308
  • Abstain: 679,014

Outlook, Risks, and Contingencies

The filing notes that the Compensation Committee may make discretionary adjustments to the incentive program based on the Company's cash resources as of December 31, 2016, and the date of payment. No specific forward-looking financial guidance or risk factors were disclosed in this report.

Key Facts for Investor Verification

  • Verify the actual base salaries of the CEO, CFO, and President to calculate potential maximum cash outlays under the new incentive plan.
  • Review the specific definitions of "Strategic," "Medical," and "Industrial" goals to assess the difficulty of achieving the 100% and 150% payout thresholds.
  • Monitor the company's cash position at year-end 2016, as the Compensation Committee explicitly reserves the right to reduce awards based on available cash resources.
  • Note the significant number of broker non-votes (34,057,300) on the director election, indicating a large portion of shares were held by brokers who did not have discretionary voting power on this matter.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.